3-month daily rifampicin and isoniazid compared to 6- or 9-month isoniazid for treating latent tuberculosis infection in children and adolescents less than 15 years of age: an updated systematic review. Issue 1 (12th July 2018)

• Record Type: Journal Article
• Authors: Assefa, Yibeltal; Assefa, Yalemzewod; Woldeyohannes, Solomon; Hamada, Yohhei; Getahun, Haileyesus
• Is Part Of: European respiratory journal. Volume 52:Issue 1(2018)
• Publication Date: 2018-07-12
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiration -- Periodicals; 616.2
• DOI: 10.1183/13993003.00395-2018
• Languages: English
• ISSNs: 0903-1936

Abstract

One-third to one-quarter of the world's population is estimated to have latent tuberculosis infection (LTBI) [1]. These infected persons are at risk for developing active disease with a lifetime risk of reactivation estimated to be 5–10% [2]. Prevention of reactivation of LTBI in population groups with higher risk of progression to active disease than the general population, is critical to end the global TB epidemic [3]. Treatment of latent tuberculosis infection in children with a 3-month daily rifampicin and isoniazid regimen is safe with better compliance, adherence and completion rate than a 6- or 9-month isoniazid monotherapy http://ow.ly/x28Z30jDfCE